Generation and characterization of an ascitogenic mesothelin-expressing tumor model

Cancer

Volumn 110, Issue 2, 2007, Pages 420-431

  Cheng, Wen Fang ^a   Hung, Chien Fu ^b   Chai, Chee Yin ^c   Chen, Chi An ^a   Lee, Chien Nan ^a   Su, Yi Ning ^a   Tseng, Wen Yin Isaac ^a   Hsieh, Chang Yao ^a   Shih, Ie Ming ^b   Wang, Tian Li ^b   Wu, T C ^b,d  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Animal model; Mesothelin; Microarray; Ovarian cancer; Tumor model

Indexed keywords

MESOTHELIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; C57BL 6 MOUSE; CANCER CELL CULTURE; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; MALIGNANT MESOTHELIOMA; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NORTHERN BLOTTING; OVARY CANCER; PANCREAS CANCER; PERITONEUM CANCER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TUMOR MODEL;

ANIMALS; ASCITES; BASE SEQUENCE; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION PROFILING; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MODELS, BIOLOGICAL; NEOPLASMS, EXPERIMENTAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS;

EID: 34547158244     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22781     Document Type: Article

References (24)

1. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000;50:7-33.
2. Schink JC. Current initial therapy of stage III and IV ovarian cancer: challenges for managed care. Semin Oncol. 1999; 26:2-7.
3. Zellos LS, Sugarbaker DJ. Multimodality treatment of diffuse malignant pleural mesothelioma. Semin Oncol. 2002; 29:41-50.
4. Nowak AK, Lake RA, Kindler HL, Robinson BW. New approaches for mesothelioma: biologies, vaccines, gene therapy, and other novel agents. Semin Oncol. 2002;29:82-96.
5. Liu J, Yang G, Thompson-Lanza JA, et al. A genetically defined model for human ovarian cancer. Cancer Res. 2004; 64:1655-1663.
6. Lichtenbeld HC, Ferarra N, Jain RK, Munn LL. Effect of local anti-VEGF antibody treatment on tumor microvessel permeability. Microvasc Res. 1999;57:357-362.
7. Rancourt C, Rogers BE, Sosnowski BA, et al. Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. Clin Cancer Res. 1998;4:2455-2461.
8. Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol. 1998;153: 1249-1256.
9. Roby KF, Taylor CC, Sweetwood JP, et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis. 2000;21:585-591.
10. Zhang L, Yang N, Garcia JR, et al. Generation of a syngeneic mouse model to study the effects of vascular, endothelial growth factor in ovarian carcinoma. Am J Pathol. 2002;161:2295-2309.
11. Conejo-Garcia JR, Benencia F, Courreges MC, et al. Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med. 2004;10:950-958.
12. Davis MR, Manning LS, Whitaker D, Garlepp MJ, Robinson BW. Establishment of a murine model of malignant mesothelioma. Int J Cancer. 1992;52:881-886.
13. Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res. 2004;10:3937-3942.
14. Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet. 2003;362: 1612-1616.
15. Scholler N, Fu N, Yang Y, et al. Soluble member(s) of the mesothelin/megakaryocyte potentiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A. 1999;96:11531-11536.
16. Halbert CL, Demers GW, Galloway DA. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J Virol. 1991;65:473-478.
17. Behrens CK, Igney FH, Arnold B, Moller P, Krammer PH. CD95 ligand-expressing tumors are rejected in anti-tumor TCR transgenic perforin knockout mice. J Immunol. 2001;166:3240-3247.
18. Andoh A, Takaya H, Saotome T, et al. Cytokine regulation of chemokine (IL-8, MCP-1, and RANTES) gene expression in human pancreatic periacinar myofibroblasts. Gastroenterology. 2000;119:211-219.
19. Cheng WF, Hung CF, Chai CY, et al. Enhancement of Sindbis virus self-replicating RNA vaccine potency by linkage of Mycobacterium tuberculosis heat shock protein 70 gene to an antigen gene. J Immunol. 2001;166:6218-6226.
20. Argani P, Iacobuzio-Donahue C, Ryu B, et al. Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res. 2001;7:3862-3868.
21. Yen MJ, Hsu CY, Mao TL, et al. Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res. 2006;12:827-831.
22. Ozols RF. Systemic therapy for ovarian cancer: current status and new treatments. Semin Oncol. 2006;33:S3-11.
23. Bhoola S, Hoskins WJ. Diagnosis and management of epithelial ovarian cancer. Obstet Gynecol. 2006;107:1399-1410.
24. Pfisterer J, Ledermann JA. Management of platinum-sensitive recurrent ovarian cancer. Semin Oncol. 2006;33:S12-16.